首页 » IVT mRNA合成服务 » 高质量mRNA，环状RNA，LNP等现货产品 » Spike mRNA (Cap1, m1Ψ)
Manual
SDS
COAs

Spike mRNA (Cap1, m1Ψ)

Spike protein of SARS-COV2 sequence has been identified during the pandemic. This Spike mRNA sequence is a synthetic construct HCV1145 Moderna (mRNA-1273) vaccine sequence. This mRNA is capped with Cap1 structure with high capping efficiency. It has 100% substituted with N1-methyl-pseudoUridine for enhanced expression and reduced immunogenicity. The mRNA has a 100A tail in its sequence, mimics a mature mRNA.
￥1000
RP-A00049

Description

Spike protein of SARS-COV2 sequence has been identified during the pandemic. This Spike mRNA sequence is a synthetic construct HCV1145 Moderna (mRNA-1273) vaccine sequence.  
 
This mRNA features: 
- A Cap 1 structure with high capping efficiency 
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response 
- GenScript’s patented UTR to enhance translation 
- A 100A poly(A) tail to mimic natural mature mRNA
产品属性
Form Liquid
Concentration 1mg/mL
Full mRNA length 4114nt
Full mRNA Molecular Weight 1324142
Storage buffer 1mM Sodium citrate, pH6.5
Storage condition Store at -20°C for short term (<3 months), store at -80°C for long term.
返回

质控参数
Appearance Clear and free of foreign particles
RNA Length Expected size band detected
RNA Content Target ± 5%
Integrity ≥ 75%
OD260/OD280 1.70 ~ 2.30
Capping Efficiency ≥ 90%
Endotoxin < 10 EU/mg
pH Target ± 0.5
返回

应用指导
Plate 3 × 10⁵ A549 cells per well in a 6-well plate. Transfect each well with 2.5 µg of mRNA using Lipofectamine™ MessengerMAX (or equivalent), following the manufacturer's instructions. Incubate cells overnight. The next day, harvest cells and stain with a primary antibody against the Spike protein, followed by a fluorescently labeled secondary antibody. Analyze Spike protein expression by flow cytometry.
返回

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.